相关文章
RELATED ARTICLES详细介绍
利格列汀杂质对照品 结构确证
随货提供:所有杂质对照品均随货提供HPLC,NMR,MS图谱及CoA证书。
杂质定制服务:我司有专业研发团队,可提供杂质定制服务,以大可能的满足您对杂质对照品的选购需求。
利格列汀杂质对照品 结构确证
中文名称 | 英文名称 |
利格列汀标准品 | Linagliptin |
利格列汀杂质1 | 2-((R)-3-aminopiperidine-1-carbonyl)-N-((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)benzamide |
利格列汀杂质2 | (R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质3 | N-Phthalimide-linagliptin |
利格列汀杂质4 | N1,N2-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide |
利格列汀杂质5 | (R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid |
利格列汀杂质6 | 8-((R)-3-aminopiperidin-1-yl)-7-((R)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione compound with 8-((R)-3-aminopiperidin-1-yl)-7-((S)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione (1:1) |
利格列汀杂质7 | Linagliptin Diene Impurity |
利格列汀杂质8 | Linagliptin Acetamide |
利格列汀杂质9 | (R)-tert-butyl (1-(1,7-di(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀杂质10 | (R)-8-(3-aminopiperidin-1-yl)-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质11 | 8-bromo-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质12 | (R)-tert-butyl (1-(3-methyl-7-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀杂质13 | (R)-8-(3-aminopiperidin-1-yl)-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质14 | (R)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-8-(piperidin-3-ylamino)-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质15 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide |
利格列汀杂质16 | (S)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质17 | (S)-Linagliptin |
利格列汀杂质18 | N-(2-acetylphenyl)-2-(8-bromo-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide |
利格列汀杂质19 | (R)-tert-butyl (1-(1-(2-((2-acetylphenyl)amino)-2-oxoethyl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀杂质20 | (R)-N-(2-acetylphenyl)-2-(8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide |
利格列汀杂质21 | (R)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀杂质22 | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质23 | (S)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀杂质24 | (R)-7-(but-2-yn-1-yl)-8-(3-((7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)amino)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀杂质25 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)formamide |
糖尿病是当前威胁人类健康的重要慢性疾病之一。根据糖尿病联盟(IDF)统计,我国糖尿病患者人数高达9860万,居球*。我国2型糖尿病领域呈现“三高一低”现状,即老年人糖尿病患病率高、肝肾功能受损患者比例高、合并多种疾病及联合用药比例较高,血糖控制达标率低,这些特点导致我国糖尿病的临床治疗需求复杂。在选择糖尿病治疗药物时,除关注降糖疗效外,还要重视药物的低血糖风险、药物相互作用、肝肾安全性及用药依从性等问题。
产品咨询
销售热线
微信公众号
移动端浏览